Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion.
By acquiring Forty Seven – named after its lead molecule - CD47 tumor cell protein - Gilead will acquire its lead candidate, Magrolimab, adding value to its immune-oncology pipeline.
CD47- is a molecule present on normal cell signifying immune system not to eat it. Cancer cells use the same signal to escape from the attack by the immune system. Magrolimab, an anti-CD47 antibody, is designed to interfere with the ability of SIRPα receptor on macrophages to recognize CD47 molecule, thus rendering cancerous cell...
